Table 2. High-throughput screening (Alphascreen^®) system for inhibitors that block the interaction between the PLZF and HB-EGF- or AR-CTF.

	Biotin-HB-EGF-CTF		Biotin-AR-CTF
	100 µM	10 µM	100 µM	10 µM
	%Inhibition		%Inhibition
No.7620	82.1	22.1	76.3	25.6
No.7632	81.7	12.6	74.9	40.5
No.7701	89.6	41.6	71.5	60.5
No.7702	86.7	34.4	77.9	46.3
No.7768	73	24.1	53.2	32.6
No.7787	82.1	10	82.2	14.9
No.7804	85.7	19.5	79.8	49.9
No.7826	82.3	14.5	82.6	30.7
No.7834	90.7	21.5	77.1	43.6
No.7887	93.9	28.4	90.9	39.5
No.7972	67.5	9.9	70.1	34.2
No.8016	71.4	33.1	75	30.4
Telmisartan	*	*	66.9	48.5
Camdesartan	78.1	12.6	84.1	23.2
Olmesartan	*	*	51.8	20.5
Losartan	*	*	68.4	12.9

Compounds: 9,000 → 12, Z’-factor: 0.73±0.091, S/B: 20.6,

^*not calculated.

Twelve candidate and four angiotensin II type 1 receptor blocker (ARB) based on efficacy for blocking binding of HB-EGF-CTF or AR-CTF to Zn5-8 of PLZF with Alphascreen system. Z’-factor showed to be 0.73 (0.5<Z’<1.0), suggesting the reliable data.